+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global GLP-1 Receptor Agonist Market by Product (Bydureon, Ozempic, Saxenda), Drug Class (Albiglutide, Dulaglutide, Exenatide), Route of Administration, Distribution Channel, Application - Forecast 2024-2030

  • PDF Icon

    Report

  • 188 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5533031
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The GLP-1 Receptor Agonist Market size was estimated at USD 4.44 billion in 2023, USD 4.92 billion in 2024, and is expected to grow at a CAGR of 11.26% to reach USD 9.38 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the GLP-1 Receptor Agonist Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the GLP-1 Receptor Agonist Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the GLP-1 Receptor Agonist Market, highlighting leading vendors and their innovative profiles. These include 9 Meters Biopharma, Inc., A-S Medication Solutions, LLC, Amgen Inc., AstraZeneca PLC, Biora Therapeutics, Inc., Eli Lilly and Company, Hanmi Pharm.Co., Ltd., Innovent Biologics (Suzhou) Ltd., Jiangsu Hengrui Medicine Co., Ltd., Merck KGaA, Novo Nordisk A/S, Optum, Inc., Paige Biomedicine (Suzhou) Co., Ltd., Pfizer Inc., and Sun Pharmaceutical Industries Limited.

Market Segmentation & Coverage

This research report categorizes the GLP-1 Receptor Agonist Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Bydureon
    • Ozempic
    • Saxenda
    • Trulicity
    • Victoza
  • Drug Class
    • Albiglutide
    • Dulaglutide
    • Exenatide
    • Liraglutide
    • Lixisenatide
    • Semaglutide
  • Route of Administration
    • Oral
    • Parenteral
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Application
    • Liver Cirrhosis
    • Non-Alcoholic Steatohepatitis
    • Obesity
    • Type 2 Diabetes Mellitus
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the GLP-1 Receptor Agonist Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the GLP-1 Receptor Agonist Market?
  3. What are the technology trends and regulatory frameworks in the GLP-1 Receptor Agonist Market?
  4. What is the market share of the leading vendors in the GLP-1 Receptor Agonist Market?
  5. Which modes and strategic moves are suitable for entering the GLP-1 Receptor Agonist Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. GLP-1 Receptor Agonist Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in the number of diabetic patients and recent advancement in the treatment of Type 2 Diabetes Mellitus
5.1.1.2. Growing number of approval for novel medications
5.1.1.3. Government awareness campaigns to curb diabetes mellitus
5.1.2. Restraints
5.1.2.1. Patent expiry of GLP-1 receptor agonist drugs
5.1.3. Opportunities
5.1.3.1. Rising new product launches and ongoing development of strong medication pipeline
5.1.3.2. Developing focus on the collaboration activities to obtain commercialization rights
5.1.4. Challenges
5.1.4.1. Severe risks and limitations such as renal impairment, pancreatitis, diabetic ketoacidosis
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. GLP-1 Receptor Agonist Market, by Product
6.1. Introduction
6.2. Bydureon
6.3. Ozempic
6.4. Saxenda
6.5. Trulicity
6.6. Victoza
7. GLP-1 Receptor Agonist Market, by Drug Class
7.1. Introduction
7.2. Albiglutide
7.3. Dulaglutide
7.4. Exenatide
7.5. Liraglutide
7.6. Lixisenatide
7.7. Semaglutide
8. GLP-1 Receptor Agonist Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. GLP-1 Receptor Agonist Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. GLP-1 Receptor Agonist Market, by Application
10.1. Introduction
10.2. Liver Cirrhosis
10.3. Non-Alcoholic Steatohepatitis
10.4. Obesity
10.5. Type 2 Diabetes Mellitus
11. Americas GLP-1 Receptor Agonist Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific GLP-1 Receptor Agonist Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa GLP-1 Receptor Agonist Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. 9 Meters Biopharma, Inc.
15.1.2. A-S Medication Solutions, LLC
15.1.3. Amgen Inc.
15.1.4. AstraZeneca PLC
15.1.5. Biora Therapeutics, Inc.
15.1.6. Eli Lilly and Company
15.1.7. Hanmi Pharm.Co., Ltd.
15.1.8. Innovent Biologics (Suzhou) Ltd.
15.1.9. Jiangsu Hengrui Medicine Co., Ltd.
15.1.10. Merck KGaA
15.1.11. Novo Nordisk A/S
15.1.12. Optum, Inc.
15.1.13. Paige Biomedicine (Suzhou) Co., Ltd.
15.1.14. Pfizer Inc.
15.1.15. Sun Pharmaceutical Industries Limited
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
List of Figures
FIGURE 1. GLP-1 RECEPTOR AGONIST MARKET RESEARCH PROCESS
FIGURE 2. GLP-1 RECEPTOR AGONIST MARKET SIZE, 2023 VS 2030
FIGURE 3. GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLP-1 RECEPTOR AGONIST MARKET DYNAMICS
FIGURE 7. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 10. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 16. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. GLP-1 RECEPTOR AGONIST MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. GLP-1 RECEPTOR AGONIST MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. GLP-1 RECEPTOR AGONIST MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 6. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY BYDUREON, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY OZEMPIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SAXENDA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY TRULICITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY VICTOZA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 12. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ALBIGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIXISENATIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 22. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 26. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIVER CIRRHOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY NON-ALCOHOLIC STEATOHEPATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY TYPE 2 DIABETES MELLITUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 47. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 48. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 52. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 53. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 74. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 79. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 89. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 119. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 134. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 135. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 140. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 141. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 145. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 146. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 150. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 155. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 165. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 166. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 180. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 181. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 185. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 190. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 191. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 210. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 225. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 226. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. GLP-1 RECEPTOR AGONIST MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 240. GLP-1 RECEPTOR AGONIST MARKET SHARE, BY KEY PLAYER, 2023
TABLE 241. GLP-1 RECEPTOR AGONIST MARKET LICENSE & PRICING

Companies Mentioned

  • 9 Meters Biopharma, Inc.
  • A-S Medication Solutions, LLC
  • Amgen Inc.
  • AstraZeneca PLC
  • Biora Therapeutics, Inc.
  • Eli Lilly and Company
  • Hanmi Pharm.Co., Ltd.
  • Innovent Biologics (Suzhou) Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck KGaA
  • Novo Nordisk A/S
  • Optum, Inc.
  • Paige Biomedicine (Suzhou) Co., Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited

Methodology

Loading
LOADING...

Table Information